The VC firm, Access BridgeGap, will back three to five early-stage therapeutics companies per year.
Len Blavatnik, head of US-based conglomerate Access industries, has committed $75m to a new venture capital (VC) firm looking for deals in US academic laboratories. The VC firm, Access BridgeGap, will back three to five early-stage therapeutics companies per year. Blavatnik said: "Access BridgeGap is an important part of Access’ growing interest in life sciences…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
